Skip to content

Clinical study on the prevention of recurrent bladder cancer after ureteral urothelial carcinoma

Clinical study on the prevention of recurrent bladder cancer after ureteral urothelial carcinoma

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400085287
Enrollment
Unknown
Registered
2024-06-04
Start date
2023-12-10
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ureteral urothelial carcinoma

Interventions

Sponsors

The First Affiliated Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? Unilateral ureteral urothelial carcinoma or unilateral ureteral urothelial carcinoma combined with bladder carcinoma were diagnosed at first (bladder sparing surgery);Patients ranged in age from 30 to 80 years; (2) Open, laparoscopic or robot-assisted laparoscopic nephreteral sleeve resection;For patients with unilateral ureteral urothelial carcinoma complicated with bladder cancer, open, laparoscopic or robot-assisted laparoscopic radical nephreteral sleeve resection +TURBT is required, excluding partial cystectomy outside the ureteral orifice. (3) The postoperative pathological type was urothelial carcinoma, with clear pathological grade and stage, and the tumor base, depth of invasion and maximum cross-section were clearly described. (4) Complete clinical data and follow-up data.

Exclusion criteria

Exclusion criteria: ? Bilateral ureteral urothelial carcinoma was first diagnosed. Perioperative neoadjuvant chemoradiotherapy or targeted therapy; (3) Incomplete pathological stage of the tumor or other pathological types of non-urothelial carcinoma diagnosed by postoperative pathology;? Incomplete clinical data or loss of follow-up during follow-up.

Design outcomes

Primary

MeasureTime frame
Recurrence rate of bladder tumor;Recurrence time of bladder tumor;Progression-free survival;Recurrence-free survival;Tumor-specific survival rate;Overall survival;Adverse drug reaction;

Countries

China

Contacts

Public ContactChuize Kong

The First Affiliated Hospital of China Medical University

kongchuize_cmu@sina.cn+86 136 0492 5361

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026